Efficacy and toxicity of Ipilimumab-Nivolumab combination therapy in elderly metastatic melanoma patients

INTRODUCTION: Immunotherapy has revolutionized metastatic Melanoma therapy. The most active regimen is combination therapy of Ipilimumab-Nivolumab (Ipi-Nivo) with response rates (RR) of ~60% and median overall survival (OS) of ~6 years. Immune-related adverse events (irAE) are common (~60% develop g...

Descripción completa

Detalles Bibliográficos
Autores principales: Stoff, Ronen, Grynberg, Shirly, Asher, Nethanel, Laks, Shachar, Steinberg, Yael, Schachter, Jacob, Shapira-Frommer, Ronnie, Ben-Betzalel, Guy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9676931/
https://www.ncbi.nlm.nih.gov/pubmed/36419899
http://dx.doi.org/10.3389/fonc.2022.1020058

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9676931/
https://www.ncbi.nlm.nih.gov/pubmed/36419899
http://dx.doi.org/10.3389/fonc.2022.1020058

Ejemplares similares